arrow
K

KyoungSoo Lim

AstraZeneca
H指数:4
被引数:88

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd) in Patients with Hormone Receptor (HR) Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Datopotamab Deruxtecan(Dato-DXd)在激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性乳腺癌患者中的暴露-反应分析

2026-04-160
OAAI
Optimal Dosage Justification for Datopotamab Deruxtecan in HR-Positive/HER2-Negative Breast Cancer Through Model-Informed Drug Development Approaches

通过模型指导的药物开发方法对datopotamab deruxtecan在HR阳性/HER2阴性乳腺癌中的最佳剂量进行合理性论证

2026-02-152
OAAI
Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

在AEGEAN III期研究中,可切除II期至IIIB(N2)期NSCLC患者中 durvalumab 的群体药代动力学和暴露-反应分析

2025-11-010
OAAI
Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer

度伐利尤单抗联合吉西他滨和顺铂在晚期胆道癌患者中的群体药代动力学和暴露-反应分析

2025-01-170
OA